Sugi Predict

Sugi Predict / Compounds / SCHEMBL231997

SCHEMBL231997

SCHEMBL231997

Nc1cc(Br)cc(F)c1N

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ DGAT1 O75907 1/20 0.34
▸ IDO1 P14902 1/20 0.33
▸ TDO2 P48775 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KDM1A O60341 2/20 0.32
▸ KDM1B Q8NB78 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31441248 1.00 CA1 (0.39) CA1CA2CA9HDAC1HDAC6
SCHEMBL58096 0.86 HDAC1 (0.44) CA1CA2CA9HDAC1HDAC6
SCHEMBL12819217 0.80 MAPT (0.40) CA1CA2CA9IDO1TDO2
SCHEMBL1639935 0.79 CA1 (0.54) CA1CA2CA9HDAC1HDAC6
SCHEMBL29865173 0.79 DGAT1 (0.34) CA1CA2CA9DGAT1IDO1
SCHEMBL25241106 0.79 ALDH1A1 (0.39) CA1CA2CA9DGAT1IDO1
SCHEMBL26088102 0.79 DGAT1 (0.34) CA1CA2CA9DGAT1IDO1
SCHEMBL9388166 0.78 GAA (0.48) CA1CA2CA9IDO1TDO2
SCHEMBL1612647 0.78 GAA (0.48) CA1CA2CA9IDO1TDO2
SCHEMBL29674869 0.78 GAA (0.48) CA1CA2CA9IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011311-A Preparation method of metal nanocluster confined covalent organic framework composite material 西北工业大学 2026-05-12 — — CN claimed
CN-112028834-B Synthesis method of Abelide intermediate 济南悟通生物科技有限公司 2022-03-29 — — CN claimed
CN-112028834-A Synthesis method of Abelide intermediate 济南悟通生物科技有限公司 2020-12-04 — — CN claimed
CN-122055363-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2026-05-15 — — CN disclosed
CN-122011311-A Preparation method of metal nanocluster confined covalent organic framework composite material 西北工业大学 2026-05-12 — — CN disclosed
WO-2026086928-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2026-04-30 — — WO disclosed
EP-4724438-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2026-04-15 — — EP disclosed
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTPR LTD (GB) 2026-03-26 — — US disclosed
US-12492188-B2 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis BRISTOL-MYERS SQUIBB COMPANY (US) 2025-12-09 — — US disclosed
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 — — US disclosed
US-20250326748-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 — — US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 — — US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 — — US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 — — US disclosed
WO-2010030785-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS INC. (US) 2010-03-18 — — WO disclosed
WO-2010020363-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-25 — — WO disclosed
WO-2009144554-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS PFIZER, INC. (US) 2009-12-03 — — WO disclosed
WO-2009134750-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 — — WO disclosed
WO-2009079011-A1 BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 CA1 3920/4885CA2 3803/4885CA9 4501/4885
US-12492188-B2 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis TLR9, TLR1, TLR7 CA1 4639/4885CA2 2114/4885CA9 2156/4885
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 CA1 971/4885CA2 809/4885CA9 1399/4885
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CSNK1A1, CSNK1G1, CSNK2A3 CA1 312/4885CA2 106/4885CA9 1341/4885
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF CYP3A5, ABAT, TPMT CA1 4457/4885CA2 4284/4885CA9 4130/4885
US-20250326748-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 CA1 4082/4885CA2 4843/4885CA9 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.